https://www.selleckchem.com/products/cp2-so4.html
Secondarily, 1 L ET-CDK4/6i followed by CT had worse OS compared to 1 L ET-CDK4/6i followed by ET. Notably, none of baseline characteristics at 2 L influenced 2 L treatment choice (ET vs. CT) after ET-CDKi. Our real-world data demonstrated that ET-CDKi represents the best option for 1 L luminal-MBC compared to ET and CT. Also, the present study pointed out that 2 L ET, potentially combined with other molecules, could be a feasible option after CDK4/6i failure, postponing CT on later lines. Our real-world data demonstrated that ET-CDKi r
Like
Comment
Share
